Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 100 for:    MOVE 2014
Previous Study | Return to List | Next Study

A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02227303
Recruitment Status : Completed
First Posted : August 28, 2014
Last Update Posted : March 24, 2015
Sponsor:
Collaborator:
Miami Research Associates
Information provided by (Responsible Party):
Medidata Solutions

Brief Summary:
The purpose of this study is to explore the effect of 8-weeks use of the Medidata Patient Cloud (a mobile application for capturing data directly from subjects, enabling entry of diary and quality of life data into internet-enabled devices) in combination with an activity tracker (Fitbit Flex) on health outcomes in overweight people with Type 2 Diabetes.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Behavioral: lifestyle modification instructional and motivational sessions Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes
Study Start Date : August 2014
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Lifestyle counseling Behavioral: lifestyle modification instructional and motivational sessions



Primary Outcome Measures :
  1. Changes from baseline to 8 weeks in glucose, insulin, fructosamine and HgbA1c [ Time Frame: 8 weeks ]
  2. Changes from baseline to 4 and 8 weeks in body weight. [ Time Frame: 4 to 8 weeks ]
  3. Changes from baseline to 4 and 8 weeks in compliance with nutrition goals as measured via dichotomous questionnaire. [ Time Frame: 4 to 8 weeks ]
  4. Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by steps per day (provided by the Fitbit Flex). [ Time Frame: 4 to 8 weeks ]
  5. Weekly changes over 8 weeks as compared to baseline in quality of life as measured by the PROMIS® Global Health questionnaire (global physical health and global mental health subscale scores and social and overall health scores). [ Time Frame: 8 weeks ]

Other Outcome Measures:
  1. Changes from baseline to 4 and 8 weeks on quality of sleep as measured via the sleep efficiency score (provided by the Fitbit Flex). [ Time Frame: 4 to 8 weeks ]
  2. Changes from baseline to 4 and 8 weeks in compliance with exercise goals as measured by active minutes (provided by the Fitbit Flex; requires subject input of data). [ Time Frame: 4 to 8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects, aged 18 to 60 years, who are English or Spanish speakers.
  2. BMI 25 to 34.9 kg/m2
  3. Subject has type 2 diabetes with HgbA1c < 8.0%
  4. Subject's glucose is controlled with either diet alone or oral agents that do not cause hypoglycemia (e.g. Metformin, DPP-4 inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors and GLP-1 agonists).
  5. Subject is motivated to increase their activity and make other lifestyle changes.
  6. Subject has:

    • A compatible Apple mobile device with the iOS 7 operating system installed:

      • iPhone 4 or newer
      • iPad 2 or newer
      • iPad Mini
      • iPod touch 5th gen (2012 model) or newer
    • 500MB of free space on the iPhone, iPad, or iPod touch
    • A valid mobile phone number to receive daily updates via SMS text messaging
    • An active iTunes account/password to install study-related software ("apps")
    • Access to Wi-Fi or a mobile data plan to send study data
  7. Female subject is surgically sterile, post-menopausal or agrees to use an acceptable method of birth control as defined in section 2.7.
  8. Subject agrees to not use any new vitamin and/or mineral supplement until after study completion.
  9. Subject agrees to not take any dietary or herbal supplements or products until after study completion. Seven-day washout period prior to study inclusion allowed.
  10. Subject is willing and able to comply with the protocol including:

    1. Attending 3 visits, approximately 2 hours each
    2. Wearing and inputting required information into the Fitbit Flex activity tracker
    3. Receiving alerts from the Medidata Patient Cloud
    4. Working on making nutrition and exercise changes over the 8-week study period
    5. Using and updating his/her iPhone, iPad, iPad Mini or iTouch as per study requirements (e.g. downloading the iOS7 operating system, downloading the Medidata Patient Cloud and Fitbit Flex apps, and receiving daily text messages).
  11. Subject is able to understand and sign the informed consent to participate in the study.

Exclusion Criteria:

  1. Subject has any of the following medical conditions:

    1. active heart disease
    2. uncontrolled high blood pressure (≥ 140/90 mmHg)
    3. renal or hepatic impairment/disease
    4. Type I diabetes
    5. bipolar disorder
    6. active psychiatric disease
    7. Parkinson's disease
    8. unstable thyroid disease
    9. immune disorder (such as HIV/AIDS)
    10. any medical condition deemed exclusionary by the Principal Investigator (PI)
  2. Subject has a history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within five years prior to screening.
  3. Subject is taking oral agents that can cause hypoglycemia (e.g. sulfonylureas, meglitinides and insulin).
  4. Subject is taking or has taken in the past 28 days any supplement or medication (prescription or over the counter) for weight loss (see section 2.6.2); 28-day washout required for study inclusion.
  5. Subject is on an unstable dose of medication (defined as fewer than 90 days at the same dose).
  6. Subject is currently taking any medication deemed exclusionary by PI.
  7. Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ 2 times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
  8. Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the electrocardiogram (ECG).
  9. Subject has a QTc interval > 450 msec for males and > 470 msec for females.
  10. Subject has a history of drug or alcohol abuse in the past 12 months.
  11. Subject has begun/stopped smoking ≤ 6 months ago OR has plans to begin/quit smoking.
  12. Subject has experienced a weight loss or gain greater than 4.5 kg (approximately 10 lbs) in the past 3 months.
  13. Subject is pregnant, lactating, or planning to become pregnant during the study period.
  14. Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
  15. Subject has taken an investigational product within 30 days of study enrollment (visit 2).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02227303


Locations
Layout table for location information
United States, Florida
Miami Research Associates (MRA)
Miami, Florida, United States, 33143
Sponsors and Collaborators
Medidata Solutions
Miami Research Associates
Investigators
Layout table for investigator information
Principal Investigator: Diane R. Krieger, MD Miami Research Associates. Miami, FL.
Publications:
Layout table for additonal information
Responsible Party: Medidata Solutions
ClinicalTrials.gov Identifier: NCT02227303    
Other Study ID Numbers: MOVE-2014
First Posted: August 28, 2014    Key Record Dates
Last Update Posted: March 24, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Overweight
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight